Stocks Health care PVCT

OTC · Health care

Provectus Biopharmaceuticals, Inc. (PVCT)

It posted a net loss of $4.7M. At June 30, 2026 it held $1.2M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.

Watch PVCT in 60 seconds

What Provectus Biopharmaceuticals, Inc. does

Provectus Biopharmaceuticals, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on OTC under the ticker PVCT.

Revenue and profit by year

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Full financial statements: income, balance sheet and cash flow

Where PVCT ranks in Health care

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Latest SEC filings

What Provectus Biopharmaceuticals, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

1. August 13, 2026
   Quarterly report 10-Q · period to June 30, 2026Diluted EPS $0.00 versus $0.00.
2. July 22, 2026
   Activist stake changed SCHEDULE 13D/A
3. July 1, 2026
   Executive or director change 8-K
4. June 22, 2026
   Shareholder vote results 8-K
5. June 18, 2026
   Investor disclosure 8-K
6. May 14, 2026
   Quarterly report 10-Q · period to March 31, 2026Diluted EPS $0.00 versus $0.00.
7. April 30, 2026
   Annual report to shareholders ARS
8. April 30, 2026
   Additional proxy material DEFA14A
9. April 30, 2026
   Proxy statement DEF 14A
10. April 21, 2026
    Other event 8-K

Recent insider filings (Forms 3, 4 and 144): 10, the latest on September 18, 2026. Insider transactions on SEC

Insider trades

What the people running Provectus Biopharmaceuticals, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider trades were reported in the last 90 days.

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns PVCT

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

We have not read this company's Form 4 filings yet.

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about PVCT

What does Provectus Biopharmaceuticals, Inc. do?

Provectus Biopharmaceuticals, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on OTC under the ticker PVCT.

Is Provectus Biopharmaceuticals, Inc. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $4.7M.

When did Provectus Biopharmaceuticals, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 18, 2026.

Similar companies

Compare PVCT with

Compare PVCT with any company

Follow PVCT

Get an email when Provectus Biopharmaceuticals, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow PVCT: get an email when it files

Where the numbers come from

Financial figures are the values Provectus Biopharmaceuticals, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.